Advertisement
Screener

ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number

ARCTURUS THERAPEUTICS HOLDINGS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number

ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number of 8.08 million shares as of 2024-12-31, per its 10-K filed 2025-03-06.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber · last filed 2025-03-06

  • 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 8.08M shares.
  • 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 7.97M shares.
  • 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 6.62M shares.
  • 2021-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 4.65M shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number
2024-12-318.08M shares
10-K · filed 2025-03-06
2023-12-317.97M shares
10-K · filed 2024-03-14
2022-12-316.62M shares
10-K · filed 2023-03-29
2021-12-314.65M shares
10-K · filed 2022-03-01
2020-12-313.32M shares
10-K · filed 2021-03-01
2019-12-311.65M shares
10-K · filed 2020-03-16
2019-06-301.24M shares
10-Q · filed 2019-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
Rezolute, Inc. (RZLT)United States$0.382B-6.45
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63